The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

類似資料

• Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
  著者:: van der Veer, Michael. S., 等
  出版事項: (2011)
• Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab
  著者:: Krejcik, Jakub, 等
  出版事項: (2017)
• Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
  著者:: Krejcik, Jakub, 等
  出版事項: (2016)
• Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
  著者:: Saltarella, Ilaria, 等
  出版事項: (2020)
• Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
  著者:: Ghose, Jayeeta, 等
  出版事項: (2018)